The Impact of Immunomodulatory Treatment on Kappa Free Light Chains as Biomarker in Neuroinflammation.
Kappa free light chains
biomarker
cerebrospinal fluid
intrathecal synthesis
multiple sclerosis
pre-analytic impact factors
serum
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
31 03 2020
31 03 2020
Historique:
received:
24
02
2020
revised:
24
03
2020
accepted:
28
03
2020
entrez:
5
4
2020
pubmed:
5
4
2020
medline:
26
2
2021
Statut:
epublish
Résumé
Kappa free light chains (KFLC) are a promising new biomarker to detect neuroinflammation. Still, the impact of pre-analytical effects on KFLC concentrations was not investigated. KFLC concentrations were measured in serum and cerebrospinal fluid (CSF) of patients with a newly diagnosed multiple sclerosis (MS) or clinically isolated syndrome (CIS) before (n = 42) or after therapy with high-dose methylprednisolone (n = 65). In prospective experiments, KFLC concentrations were analyzed in the same patients in serum before and after treatment with high-dose methylprednisolone (n = 16), plasma exchange (n = 12), immunoadsorption (n = 10), or intravenous immunoglobulins (n = 10). In addition, the influence of storage time, sample method, and contamination of CSF with blood were investigated. Patients diagnosed with MS/CIS and treated with methylprednisolone showed significantly lower KFLC concentrations in serum as untreated patients. Repeated longitudinal investigations revealed that serum KFLC concentrations continuously decreased after each application of methylprednisolone. In contrast, other immune therapies and further pre-analytical conditions did not influence KFLC concentrations. Our results show prominent effects of steroids on KFLC concentrations. In contrast, various other pre-analytical conditions did not influence KFLC concentrations, indicating the stability of this biomarker.
Sections du résumé
BACKGROUND
Kappa free light chains (KFLC) are a promising new biomarker to detect neuroinflammation. Still, the impact of pre-analytical effects on KFLC concentrations was not investigated.
METHODS
KFLC concentrations were measured in serum and cerebrospinal fluid (CSF) of patients with a newly diagnosed multiple sclerosis (MS) or clinically isolated syndrome (CIS) before (n = 42) or after therapy with high-dose methylprednisolone (n = 65). In prospective experiments, KFLC concentrations were analyzed in the same patients in serum before and after treatment with high-dose methylprednisolone (n = 16), plasma exchange (n = 12), immunoadsorption (n = 10), or intravenous immunoglobulins (n = 10). In addition, the influence of storage time, sample method, and contamination of CSF with blood were investigated.
RESULTS
Patients diagnosed with MS/CIS and treated with methylprednisolone showed significantly lower KFLC concentrations in serum as untreated patients. Repeated longitudinal investigations revealed that serum KFLC concentrations continuously decreased after each application of methylprednisolone. In contrast, other immune therapies and further pre-analytical conditions did not influence KFLC concentrations.
CONCLUSION
Our results show prominent effects of steroids on KFLC concentrations. In contrast, various other pre-analytical conditions did not influence KFLC concentrations, indicating the stability of this biomarker.
Identifiants
pubmed: 32244362
pii: cells9040842
doi: 10.3390/cells9040842
pmc: PMC7226742
pii:
doi:
Substances chimiques
Biomarkers
0
Immunoglobulin Light Chains
0
Immunoglobulin kappa-Chains
0
Immunoglobulins, Intravenous
0
Immunologic Factors
0
Methylprednisolone
X4W7ZR7023
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Ann Intern Med. 2005 Dec 6;143(11):777-84
pubmed: 16330788
PLoS One. 2014 Apr 02;9(4):e88680
pubmed: 24695382
Front Neurol. 2019 Jun 12;10:584
pubmed: 31249547
Int J Mol Sci. 2018 Nov 29;19(12):
pubmed: 30501024
Arch Neurol. 1987 Aug;44(8):803-7
pubmed: 2820358
Clin Chim Acta. 2014 Jan 1;427:15-20
pubmed: 23999048
Methods Enzymol. 1985;116:101-21
pubmed: 3937021
Mult Scler. 1998 Jun;4(3):99-107
pubmed: 9762655
Arch Neurol. 1988 Jun;45(6):669-70
pubmed: 3369975
Kidney Int. 2008 Jun;73(11):1282-8
pubmed: 18385667
Lancet Neurol. 2013 Feb;12(2):157-65
pubmed: 23290630
Int J Mol Sci. 2016 Sep 21;17(9):
pubmed: 27657060
Neurology. 1970 Oct;20(10):982-90
pubmed: 4097237
BMC Neurol. 2015 Dec 11;15:255
pubmed: 26830688
Am J Hematol. 1983 Aug;15(1):75-88
pubmed: 6410911
Scand J Clin Lab Invest. 1977 Sep;37(5):397-401
pubmed: 337461
Clin Chem. 2007 Aug;53(8):1557-8
pubmed: 17644797
Arch Neurol. 1980 Oct;37(10):620-4
pubmed: 6252876
Eur J Neurol. 2018 Sep;25(9):1134-1139
pubmed: 29683546
Restor Neurol Neurosci. 2003;21(3-4):79-96
pubmed: 14530572
J Clin Apher. 2018 Jun;33(3):439-443
pubmed: 29427353
ScientificWorldJournal. 2011 Mar 22;11:726-35
pubmed: 21442150
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Semin Hematol. 1989 Apr;26(2 Suppl 1):31-41
pubmed: 2543085
Mult Scler. 2015 Jul;21(8):1013-24
pubmed: 25680984
Neurology. 1980 Jul;30(7 Pt 1):702-8
pubmed: 6967197
Clin Chem. 1995 Feb;41(2):256-63
pubmed: 7874779
Immunology. 1975 Apr;28(4):669-80
pubmed: 1080130
J Neuroimmunol. 2010 Dec 15;229(1-2):263-71
pubmed: 20870296
Lancet Neurol. 2018 Jun;17(6):498
pubmed: 29778358
J Am Soc Nephrol. 2011 Jun;22(6):1129-36
pubmed: 21511832
Neurology. 1986 Feb;36(2):238-43
pubmed: 3511404
Int J Mol Sci. 2017 Sep 27;18(10):
pubmed: 28953254
J Clin Invest. 1974 Jan;53(1):240-6
pubmed: 4808638
J Neurol. 2008 Oct;255(10):1508-14
pubmed: 18685917
Neurology. 1982 Mar;32(3):261-6
pubmed: 6278361
Cell Immunol. 1986 Aug;101(1):122-31
pubmed: 3091263
Nat Rev Neurol. 2013 May;9(5):267-76
pubmed: 23528543
J Vet Intern Med. 1991 Mar-Apr;5(2):95-104
pubmed: 2061872
Brain. 2015 Jul;138(Pt 7):1863-74
pubmed: 25902415
Am J Clin Dermatol. 2007;8(5):291-9
pubmed: 17902731
Diagnostics (Basel). 2019 Nov 16;9(4):
pubmed: 31744096
Acta Neurol Scand. 1992 Sep;86(3):291-7
pubmed: 1384263
Clin Chim Acta. 2019 Oct;497:153-162
pubmed: 31351929
Clin Chim Acta. 1990 Mar 15;187(3):297-308
pubmed: 2323069
Clin Exp Immunol. 2011 Jun;164 Suppl 2:2-5
pubmed: 21466545
Transfusion. 2007 Mar;47(3):511-4
pubmed: 17319833
J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):897-902
pubmed: 8057110
Arq Neuropsiquiatr. 2016 Apr;74(4):337-50
pubmed: 27097008